Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation

被引：19

作者：

Shen, YH

Xie, Q

Norberg, M

Sausville, E

Woude, GV

Wenkert, D ^{[1
]}

机构：

[1] Michigan State Univ, Dept Physiol, E Lansing, MI 48864 USA

[2] Van Andel Res Inst, Grand Rapids, MI 49503 USA

[3] NCI, Div Canc Treatment & Diagnosis, Bethesda, MD 20892 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2005年 / 13卷 / 16期

关键词：

geldanamycin; hepatocyte growth factor/scatter factor; urokinase-plasminogen activation; Met tyrosine kinase receptor;

D O I：

10.1016/j.bmc.2005.05.038

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Ansamycins including geldanamycin and the derivative 17-allylamino-17-demethoxygeldanamyein, and radicicol are known for their ability to tightly bind to the ATP-binding site of the amino-terminal domain region of heat shock protein 90. We have found that geldanamycin and some of its derivatives can inhibit hepatocyte growth factor/scatter factor-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation at femtomolar levels. Assessment is made of structural requirements for such an activity and evidence is given that distinguishes the target of Such all activity from that of heat shock protein 90. (c) 2005 Elsevier Ltd. All rights reserved.

引用

收藏

页码：4960 / 4971

页数：12

相关论文

共 63 条

[1] Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression [J].

Abounader, R ;

Ranganathan, S ;

Lal, B ;

Fielding, K ;

Book, A ;

Dietz, H ;

Burger, P ;

Laterra, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1548-1556

[2] In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis [J].

Abounader, R ;

Lal, B ;

Luddy, C ;

Koe, G ;

Davidson, B ;

Rosen, EM ;

Laterra, J .

FASEB JOURNAL, 2001, 15 (13) :108-+

[3]

Allen C. F. H., 1963, ORG SYNTH, P433

[4] The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future [J].

Banerji, Udai ;

Judson, Ian ;

Workman, Paul .

CURRENT CANCER DRUG TARGETS, 2003, 3 (05) :385-390

[5] Met, metastasis, motility and more [J].

Birchmeier, C ;

Birchmeier, W ;

Gherardi, E ;

Vande Woude, GF .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925

[6] Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90 [J].

Blagosklonny, MV ;

Toretsky, J ;

Bohen, S ;

Neckers, L .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8379-8383

[7] Genetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteins [J].

Bohen, SP .

MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (06) :3330-3339

[8] THE OXIDATION OF SOME AROMATIC AMINES WITH PERSULPHATE [J].

BOYLAND, E ;

SIMS, P .

JOURNAL OF THE CHEMICAL SOCIETY, 1954, (MAR) :980-985

[9] Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models [J].

Cao, B ;

Su, YL ;

Oskarsson, M ;

Zhao, P ;

Kort, EJ ;

Fisher, RJ ;

Wang, LM ;

Vande Woude, GF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7443-7448

[10] Filter binding assay for the geldanamycin-heat shock protein 90 interaction [J].

Carreras, CW ;

Schirmer, A ;

Zhong, ZY ;

Santi, DV .

ANALYTICAL BIOCHEMISTRY, 2003, 317 (01) :40-46

← 1 2 3 4 5 6 7 →